Have you lost money investing in Centessa Pharmaceuticals? If yes, please visit us Class Action by Centessa Pharmaceuticals plc Shareholders or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.
NEW YORK, Oct. 25, 2022 (GLOBE NEWSWIRE) — Bernstein Liebhard LLP, a nationally recognized investor rights law firm, is reminding investors of the deadline for filing a lead plaintiff’s motion in a securities class action lawsuit filed on behalf of investors who purchased or otherwise have acquired: (a) Centessa Pharmaceuticals plc (“Centessa” or the “Company”) CNTA American Depositary Shares (“ADSs”) pursuant to and/or traceable to the offering documents issued in connection with the Company’s initial public offering (the “IPO” or the “Offering”) on or about May 28, 2021; and/or (b) Centessa Securities between 28 May 2021 and 1 June 2022, both dates inclusive (the “Collection Period”). The lawsuit was filed in the United States District Court for the Central District of California alleging violations of the Securities Act of 1933 and the Securities Exchange Act of 1934.
Centessa is a clinical-stage pharmaceutical company that purports to discover, develop and deliver medicines to patients. The Company’s development pipeline includes Lixivaptan, a small molecule vasopressin V2 receptor inhibitor in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease (“ADPKD”); and ZF874, a small molecule pharmacological chaperone-fold corrector of the Z variant of the DNA-encoding protein alpha-1-antitrypsin (“A1AT”) in Phase 1 clinical development for the treatment of A1AT deficiency (“AATD”).
On April 21, 2021, Centessa filed a registration statement on Form S-1 with the SEC in connection with the IPO, which, after several amendments, was declared effective by the SEC on May 27, 2021 (the “Registration Statement”).
On or about May 28, 2021, Centessa conducted the…
